HER2+ Genitourinary Cancers: Targeted Therapy Highlights From ESMO 2025

from Medical News Podcast · host PeerDirect Publishing

Drs. Mantia and Berg continue their discussion of ESMO 2025 data on HER2‑directed antibody–drug conjugates in urothelial cancer and the importance of routine HER2 testing. They highlight the promising efficacy and manageable toxicity of these agents across disease stages and raise future questions about how best to sequence them.

Episode metadata supplied by the publisher feed · Published May 22, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

HER2+ Genitourinary Cancers: Targeted Therapy Highlights From ESMO 2025

0:00 14:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical News Podcast?

This episode is 14 minutes long.

When was this Medical News Podcast episode published?

This episode was published on May 22, 2026.

Can I download this Medical News Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!